Gan & Lee Pharmaceuticals vs Integer: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Gan & Lee Pharmaceuticals Co Ltd (603087.CG)

Q3 202627 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

September 202627 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

Latest27 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

Integer Holdings Corp (ITGR)

Q3 202617 Jul – 29 Sep 2026

▲1▼1

KKR's $127/share buyout drives ITGR, with approval risk remaining

KKR buyout at $127 per share KKR agreed to buy Integer for $127 per share in cash, a $5.7 billion deal at a 51.8% premium. The stock now trades near the offer, so price reflects the deal, not company performance.
This is the dominant new event that now defines ITGR's stock price.
Deal approval still pending Financing is secured, but the deal still needs shareholder and regulatory approval. Analysts downgraded to neutral, and fair-value estimates of $112–$139 sit around the offer, showing limited upside unless a higher bid emerges.
It explains the main remaining risks and why the stock trades near the offer.
Weak Q2 results and withdrawn guidance Q2 profit fell to $23.6 million from $37 million, revenue slipped 2.6%, and gross margin narrowed to 24.3%. Management withdrew guidance and canceled its earnings call, removing forward-looking data for investors.
It is the key counterweight showing underlying business weakness behind the deal.
Investor-rights review may seek higher bid An investor-rights law firm is reviewing whether $127 is fair and may seek a higher bid. This creates a small chance of a bump, but also adds uncertainty around the deal's final price.
It highlights a potential upside catalyst and a source of deal uncertainty.

August 20263 Aug – 29 Sep 2026

▲1▼1

KKR's $127 Cash Buyout Sets ITGR's Price, Despite Weak Q2

KKR buyout locks in $127 cash per share Integer agreed to be bought by KKR for $127 per share in cash, a $5.7 billion deal. That price now anchors the stock, because shareholders expect to receive it when the deal closes. The buyer already has financing, so the main remaining hurdles are a shareholder vote and regulatory approvals.
The buyout is the single force now setting ITGR's price and the main answer to why it moves.
Weak Q2 profit and sales, margins squeezed Second-quarter profit fell to $23.61 million from $37.01 million, and revenue slipped 2.6% to $464.1 million. Gross margin shrank to 24.3% from 27.1%. This weak operating picture is a counterweight: it shows the business was softening even as the buyout price caps the stock.
It is the main negative fundamental fact and the real counterweight to the buyout.
Company drops guidance and earnings call Integer withdrew its financial outlook and canceled its quarterly earnings call, saying merger progress now matters more than operating targets. For investors this removes forward-looking numbers, so the stock trades on deal news rather than company performance. It also signals management is focused on closing the KKR sale.
It explains why ordinary operating news no longer drives the stock and why the deal dominates.
Law firm review may seek a higher price An investor-rights law firm is investigating whether the $127-per-share KKR sale is fair and may push for more money or extra disclosures. Such reviews are common in buyouts. If they lead to a raised bid, the stock could rise above $127; if not, they are mostly noise.
It is the only new event that could change the deal price, so it matters to the buyout story.

Latest3 Aug – 29 Sep 2026

▲1▼1

KKR's $127 Cash Buyout Sets ITGR's Price, Despite Weak Q2

KKR buyout locks in $127 cash per share Integer agreed to be bought by KKR for $127 per share in cash, a $5.7 billion deal. That price now anchors the stock, because shareholders expect to receive it when the deal closes. The buyer already has financing, so the main remaining hurdles are a shareholder vote and regulatory approvals.
The buyout is the single force now setting ITGR's price and the main answer to why it moves.
Weak Q2 profit and sales, margins squeezed Second-quarter profit fell to $23.61 million from $37.01 million, and revenue slipped 2.6% to $464.1 million. Gross margin shrank to 24.3% from 27.1%. This weak operating picture is a counterweight: it shows the business was softening even as the buyout price caps the stock.
It is the main negative fundamental fact and the real counterweight to the buyout.
Company drops guidance and earnings call Integer withdrew its financial outlook and canceled its quarterly earnings call, saying merger progress now matters more than operating targets. For investors this removes forward-looking numbers, so the stock trades on deal news rather than company performance. It also signals management is focused on closing the KKR sale.
It explains why ordinary operating news no longer drives the stock and why the deal dominates.
Law firm review may seek a higher price An investor-rights law firm is investigating whether the $127-per-share KKR sale is fair and may push for more money or extra disclosures. Such reviews are common in buyouts. If they lead to a raised bid, the stock could rise above $127; if not, they are mostly noise.
It is the only new event that could change the deal price, so it matters to the buyout story.

July 202617 Jul – 6 Aug 2026

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.
This is the single new event that now sets ITGR's price, so it is the core answer.
No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.
Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.
Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.
Gives the honest counterweight: upside is limited and tied to completion, not to the business.
Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.
It is the only negative force this period, but the buyout has largely overtaken it.

17 Jul – 6 Aug 2026

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.
This is the single new event that now sets ITGR's price, so it is the core answer.
No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.
Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.
Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.
Gives the honest counterweight: upside is limited and tied to completion, not to the business.
Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.
It is the only negative force this period, but the buyout has largely overtaken it.